David A. Siegel Cellectar Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.5 - $6.9 $37,450 - $73,830	-10,700 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.6 - $7.8 $489,899 - $830,700	-106,500 Reduced 90.87%	10,700 $7,000
Q4 2021 Feb 14, 2022	BUY	$6.1 - $10.2 $350,140 - $585,480	57,400 Added 95.99%	117,200 $78,000
Q3 2021 Nov 15, 2021	SELL	$8.2 - $12.4 $2.39 Million - $3.61 Million	-291,000 Reduced 82.95%	59,800 $55,000
Q2 2021 Aug 16, 2021	SELL	$11.8 - $18.2 $3.47 Million - $5.35 Million	-293,800 Reduced 45.58%	350,800 $417,000
Q1 2021 May 17, 2021	BUY	$15.2 - $25.0 $9.8 Million - $16.1 Million	644,600 New	644,600 $1.04 Million
Q3 2020 Nov 16, 2020	SELL	$10.6 - $16.6 $586,180 - $917,980	-55,300 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.3 - $17.3 $569,590 - $956,690	55,300 New	55,300 $71,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $9.17M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.